Edition:
United Kingdom

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

617.50GBp
16 Nov 2018
Change (% chg)

-11.50 (-1.83%)
Prev Close
629.00
Open
635.50
Day's High
639.50
Day's Low
617.50
Volume
1,035,501
Avg. Vol
853,713
52-wk High
784.00
52-wk Low
467.40

Latest Key Developments (Source: Significant Developments)

BTG H1 Rev, Adj. Operating Profit Rises; Raises FY Pharmaceuticals Sales Forecast
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - BTG PLC ::H1 REVENUE 495.7 MILLION USD VERSUS 442.2 MILLION USD YEAR AGO.REITERATE OUR FULL-YEAR GUIDANCE FOR INTERVENTIONAL ONCOLOGY AND VASCULAR SALES.UPGRADE FY PHARMACEUTICALS SALES GUIDANCE FOLLOWING A GOOD H1 PERFORMANCE AND A VERY STRONG OCTOBER FOR CROFAB.DELIVERED 10% SALES GROWTH WITH GOOD OPERATING LEVERAGE IN OUR PRODUCT BUSINESS IN FIRST SIX MONTHS.VARITHENA NOW EXPECTED TO BE PROFITABLE NEXT YEAR AND TO BE A GROWTH DRIVER IN VASCULAR PORTFOLIO.SEES 2018/19 CER INTERVENTIONAL ONCOLOGY + VASCULAR SALES GROWTH OF 15%-17%.SEES 2018/19 CER PHARMACEUTICALS SALES TO INCREASE IN LOW SINGLE-DIGITS.HY ADJUSTED OPERATING PROFIT $178.5 MILLION VERSUS $128.1 MILLION.HY IFRS OPERATING PROFIT $97.6 MILLION VERSUS $21.8 MILLION.  Full Article

BTG upgrades product sales guidance
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - BTG PLC ::HAVE DELIVERED GOOD PRODUCT SALES GROWTH DURING FIRST HALF, DRIVEN BY PERFORMANCE OF INTERVENTIONAL MEDICINE.WE ARE UPDATING OUR GUIDANCE FOR COMBINED ONCOLOGY AND VASCULAR CER(1) PRODUCT SALES GROWTH TO 15-17% FOR YEAR.PHARMACEUTICALS PERFORMED WELL IN FIRST HALF AND WE NOW EXPECT SALES FOR YEAR TO BE AROUND UPPER END OF OUR GUIDANCE RANGE..  Full Article

BTG Announces Policy For Replacement Of Expired Vials Of Crofab
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - BTG PLC ::ANNOUNCED POLICY FOR REPLACEMENT OF EXPIRED VIALS OF CROFAB, ALLOWING CUSTOMERS TO RETURN PRODUCT FOR REPLACEMENT UP TO 90 DAYS AFTER EXPIRATION.CHANGE IN POLICY FOR EXPIRED CROFAB GOES INTO EFFECT IMMEDIATELY.  Full Article

BTG Plc Acquires Novate Medical Ltd
Friday, 7 Sep 2018 

Sept 7 (Reuters) - BTG PLC ::BTG PLC ACQUIRES NOVATE MEDICAL LTD.PAID $20M IN CASH TO ACQUIRE NOVATE AND MAY BE REQUIRED TO PAY ADDITIONAL CASH CONSIDERATIONS UP TO $130M.TRANSACTION IS EXPECTED TO BE ACCRETIVE TO ADJUSTED EPS FROM SECOND FULL YEAR OF OWNERSHIP.  Full Article

BTG Gets Not-Approvable Letter From U.S. FDA For ELEVAIR
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - BTG PLC ::BTG RECEIVES NOT-APPROVABLE LETTER FROM US FDA FOR ELEVAIR.PNEUMRX HAS RECEIVED CONFIRMATION FROM US FOOD AND DRUG ADMINISTRATION (FDA) THAT PREMARKET APPROVAL (PMA) APPLICATION FOR ITS ELEVAIR ENDOBRONCHIAL COIL SYSTEM FOR TREATMENT OF PEOPLE WITH SEVERE EMPHYSEMA IS NOT APPROVABLE.THIS FOLLOWS FDA ADVISORY PANEL'S RECOMMENDATION IN JUNE 2018 NOT TO APPROVE ELEVAIR.BTG IS REVIEWING OPTIONS AND WILL PROVIDE AN UPDATE IN DUE COURSE.PNEUMRX CONFIRMATION FROM FDA THAT PREMARKET APPROVAL APPLICATION FOR ELEVAIR ENDOBRONCHIAL COIL SYSTEM IS NOT APPROVABLE.  Full Article

BTG PLC Reiterates Guidance For Full Year
Wednesday, 18 Jul 2018 

July 18 (Reuters) - BTG PLC ::TRADING SINCE 1 APRIL 2018 IS IN LINE WITH EXPECTATIONS AND BOARD REITERATES ITS GUIDANCE FOR FULL YEAR.  Full Article

BTG full-year operating profit up 18 pct
Tuesday, 15 May 2018 

May 15 (Reuters) - BTG PLC ::FY REVENUE 620.5 MILLION STG, UP 9 PERCENT.ADJUSTED OPERATING PROFIT 152.7 MILLION STG, UP 18 PERCENT.ADJUSTED BASIC EPS 1 32.9P UP 42 PERCENT.  Full Article

BTG says 2017/18 results hit by 150 million pound impairment charge
Thursday, 5 Apr 2018 

April 5 (Reuters) - BTG PLC ::BTG HAS DELIVERED A GOOD FINANCIAL PERFORMANCE FOR YEAR, WITH REVENUE IN LINE WITH EXPECTATIONS.VERY GOOD GROWTH IN INTERVENTIONAL MEDICINE PRODUCT SALES REFLECTS MID-TEENS CER 1 GROWTH IN ONCOLOGY AND VASCULAR PORTFOLIOS, WHICH TOGETHER REPRESENT >90% OF REVENUE IN THIS BUSINES.LOWER SALES OF PNEUMRX ® COILS REFLECT THAT MARKET DEVELOPMENT, INCLUDING SECURING APPROPRIATE LEVELS OF REIMBURSEMENT, IS TAKING LONGER THAN EXPECTED.WE DO NOT EXPECT MATERIAL REVENUES FROM THIS PRODUCT OVER NEXT TWO YEARS.WE HAVE THEREFORE REASSESSED FAIR VALUE OF THIS ASSET, AND OUR FINANCIAL RESULTS FOR 2017/18 WILL INCLUDE AN IMPAIRMENT CHARGE OF APPROXIMATELY £150M.IN ADDITION, OUR 2018/19 RESULTS WILL INCLUDE A ONE-OFF RESTRUCTURING CHARGE OF UP TO £10M.  Full Article

BTG says Zytiga royalties guidance unchanged after patent setback
Wednesday, 17 Jan 2018 

Jan 18 (Reuters) - BTG ::SPOKESMAN SAYS PREVIOUS GUIDANCE ON ZYTIGA ROYALTIES IS UNCHANGED, DESPITE U.S. ADMINISTRATIVE COURT DECISION TO INVALIDATE PATENT.BELIEVES EARLIEST LIKELY U.S. GENERIC ENTRY WOULD BE OCTOBER 2018, WHICH IS ALREADY REFLECTED IN THE CONSENSUS OF ANALYSTS.  Full Article

BTG says CFO Rolf Soderstrom to step down as executive director
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BTG PLC ::THAT AFTER 10 YEARS AS CHIEF FINANCIAL OFFICER (CFO) AT BTG, ROLF SODERSTROM IS TO STEP DOWN AS AN EXECUTIVE DIRECTOR OF COMPANY​.‍INTENDS TO APPOINT DUNCAN KENNEDY TO SUCCEED ROLF AS CFO ON 1 JANUARY 2018​.‍ROLF WILL REMAIN WITH COMPANY UNTIL COMPLETION OF A SMOOTH HANDOVER TO DUNCAN, WHICH IS EXPECTED TO BE CONCLUDED BY 31 MARCH 2018​.  Full Article

UPDATE 1-Stronger pounds weighs on FTSE, offsetting Vodafone uplift

* Experian, Melrose, BTG gain after results (Adds detail, updates prices)